B J Cohen1, D Doblas, N Andrews. 1. Virus Reference Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom. Bernard.Cohen@hpa.org.uk
Abstract
BACKGROUND: Plaque reduction neutralisation test (PRNT) is a gold standard assay for measles antibodies. PRNT, however, is time-consuming and more difficult to standardise than ELISA. METHODS: PRNT results were obtained on pre- and post-vaccination sera from 501 measles-vaccinated infants. From this cohort a sub-set of 210 infants were selected for testing by ELISA, which was performed either manually or by an automated processor. Results were corrected for sampling proportion before comparing the assays. RESULTS: Seroconversion was detected by PRNT in 454 infants of whom 324 were estimated to have seroconverted by manual ELISA and 191 by automated ELISA It is recommended that ELISA negative post-vaccination samples are re-tested by PRNT to detect all seroconversions.
BACKGROUND: Plaque reduction neutralisation test (PRNT) is a gold standard assay for measles antibodies. PRNT, however, is time-consuming and more difficult to standardise than ELISA. METHODS: PRNT results were obtained on pre- and post-vaccination sera from 501 measles-vaccinated infants. From this cohort a sub-set of 210 infants were selected for testing by ELISA, which was performed either manually or by an automated processor. Results were corrected for sampling proportion before comparing the assays. RESULTS: Seroconversion was detected by PRNT in 454 infants of whom 324 were estimated to have seroconverted by manual ELISA and 191 by automated ELISA It is recommended that ELISA negative post-vaccination samples are re-tested by PRNT to detect all seroconversions.
Authors: Donald R Latner; Marcia McGrew; Nobia J Williams; Sun B Sowers; William J Bellini; Carole J Hickman Journal: Clin Vaccine Immunol Date: 2013-12-26
Authors: Benjamin M Stermole; Greg A Grandits; Mollie P Roediger; Brychan M Clark; Anuradha Ganesan; Amy C Weintrob; Nancy F Crum-Cianflone; Tomas M Ferguson; Grace E Macalino; Michael L Landrum Journal: Vaccine Date: 2011-02-23 Impact factor: 3.641
Authors: Lenesha Warrener; Josephine Bwogi; Nick Andrews; Dhanraj Samuel; Theopista Kabaliisa; Henry Bukenya; Kevin Brown; Martha H Roper; David A Featherstone; David Brown Journal: Epidemiol Infect Date: 2018-05-09 Impact factor: 4.434
Authors: Cristina V Cardemil; Anna Jonas; Anita Beukes; Raydel Anderson; Paul A Rota; Bettina Bankamp; Howard E Gary; Souleymane Sawadogo; Sadhna V Patel; Sikota Zeko; Clementine Muroua; Esegiel Gaeb; Kathleen Wannemuehler; Sue Gerber; James L Goodson Journal: Int J Infect Dis Date: 2016-05-24 Impact factor: 3.623
Authors: Shelly Bolotin; Alberto Severini; Todd Hatchette; Elizabeth McLachlan; Rachel Savage; Stephanie L Hughes; John Wang; Shelley L Deeks; Sarah Wilson; Marc Brisson; Scott A Halperin; Jonathan Gubbay; Tony Mazzulli; Bouchra Serhir; Brian J Ward; Natasha Crowcroft Journal: Hum Vaccin Immunother Date: 2019-07-16 Impact factor: 3.452
Authors: Iana H Haralambieva; Whitney L Simon; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland Journal: Viruses Date: 2015-03-10 Impact factor: 5.048